Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
140.57
-1.31 (-0.92%)
Sep 15, 2025, 10:27 AM EDT - Market open
Neurocrine Biosciences Revenue
Neurocrine Biosciences had revenue of $687.50M in the quarter ending June 30, 2025, with 16.49% growth. This brings the company's revenue in the last twelve months to $2.51B, up 18.42% year-over-year. In the year 2024, Neurocrine Biosciences had annual revenue of $2.36B with 24.81% growth.
Revenue (ttm)
$2.51B
Revenue Growth
+18.42%
P/S Ratio
5.65
Revenue / Employee
$1,394,389
Employees
1,800
Market Cap
13.94B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.36B | 468.20M | 24.81% |
Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NBIX News
- 5 days ago - Neurocrine Biosciences, Inc. (NBIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 11 days ago - Neurocrine Biosciences, Inc. (NBIX) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 19 days ago - Neurocrine Biosciences to Present at Upcoming Investor Conferences in September - PRNewsWire
- 5 weeks ago - Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference - PRNewsWire
- 6 weeks ago - Neurocrine Biosciences Positioned For Growth And New Potential Blockbusters - Seeking Alpha
- 6 weeks ago - Neurocrine Biosciences, Inc. (NBIX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Neurocrine Biosciences Reports Second Quarter 2025 Financial Results - PRNewsWire
- 2 months ago - Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition - PRNewsWire